Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.32 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6105579 | 0.87 | ERN1 (0.43) | ERN1PTGDR2ALDH1A3CYP2A6ALDH1A1 | |
| SCHEMBL6104215 | 0.83 | ALDH1A3 (0.48) | ERN1PTGDR2ALDH1A3CYP2A6ALDH1A1 | |
| SCHEMBL6105516 | 0.82 | KDM4E (0.38) | PTGDR2ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL6105521 | 0.82 | KDM4E (0.38) | PTGDR2ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL6103197 | 0.81 | ALDH3A1 (0.47) | ERN1PTGDR2ALDH1A3CYP2A6ALDH1A1 | |
| SCHEMBL3209434 | 0.79 | ERN1 (0.52) | ERN1PTGDR2ALDH1A3CYP2A6ALDH1A1 | |
| SCHEMBL31457111 | 0.79 | ERN1 (0.52) | ERN1PTGDR2ALDH1A3CYP2A6ALDH1A1 | |
| SCHEMBL6102737 | 0.79 | ALDH1A3 (0.46) | ERN1PTGDR2ALDH1A3CYP2A6ALDH1A1 | |
| SCHEMBL6104478 | 0.75 | ERN1 (0.41) | ERN1PTGDR2ALDH1A3CYP2A6ALDH1A1 | |
| SCHEMBL6517350 | 0.75 | PTGDR2 (0.40) | ERN1PTGDR2ALDH1A3ALDH1A1ALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160864-A1 | Acrylamide derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1593673-A1 | ACRYLAMIDE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160864-A1 | Acrylamide derivative, process for producing the same, and use | CCR5, MSR1, CCR2 | ERN1 1319/4885PTGDR2 1264/4885ALDH1A3 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.